The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Osteoporosis International

• Publication date

  2002-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s001980200108PMID 12378366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography

  2004cited by this paper
• Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content

  2004cited by this paper
• Prednisone-induced bone loss

  2002cited by this paper
• Oral Glucocorticoid-Induced Fall in Cortical Bone Volume and Density in Postmenopausal Asthmatic Patients

  2001cited by this paper
• Glucocorticoid-induced osteoporosis.

  2001cited by this paper
• Public health impact of adverse bone effects of oral corticosteroids.

  2001cited by this paper
• Adverse effects of oral corticosteroids in relation to dose in patients with lung disease

  2001cited by this paper
• Effects of inhaled glucocorticoids on bone density in premenopausal women.

  2001cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

  2001cited by this paper
• Primary Prevention of Glucocorticoid‐Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1‐Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone

  2001cited by this paper
• Use of inhaled corticosteroids and risk of fractures.

  2001cited by this paper
• Comparison of Calcaneal Ultrasound and DXA to Assess the Risk of Corticosteroid-Induced Osteoporosis: A Cross-sectional Study

  2001cited by this paper
• Use of Inhaled Corticosteroids and Risk of Fractures

  2001cited by this paper
• Forearm bone mineral density by age in 7,620 men and women: the Tromsø study, a population-based study.

  2001cited by this paper
• Osteoporosis with low dose corticosteroids: contribution of underlying disease effects and discriminatory ability of ultrasound versus bone densitometry.

  2001cited by this paper
• Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine.

  2000cited by this paper
• Use of oral corticosteroids in the United Kingdom.

  2000cited by this paper
• Acute Alteration in Bone Mineral Density and Biochemical Markers for Bone Metabolism in Nephrotic Patients Receiving High-Dose Glucocorticoid and One-Cycle Etidronate Therapy

  2000cited by this paper
• Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.

  2000cited by this paper
• Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men

  2000cited by this paper
• Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.

  2000cited by this paper
• Corticosteroids Do Not Alter the Threshold for Vertebral Fracture

  2000cited by this paper
• Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial.

  2000cited by this paper
• The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results

  2000cited by this paper
• Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica – a prospective study on the influence of glucocorticoid therapy

  2000cited by this paper
• Estudio densitométrico en mujeres posmenopáusicas con artritis reumatoide tratadas con dosis bajas de glucocorticoides

  2000cited by this paper
• Long‐Term Corticosteroid Therapy Induces Mild Changes in Trabecular Bone Texture

  2000cited by this paper
• Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?

  2000cited by this paper
• No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids.

  2000cited by this paper
• [Study of bone mineral density in postmenopausal women with rheumatoid arthritis treated with low dose glucocorticoids].

  2000cited by this paper
• Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

  2000cited by this paper
• Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use.

  2000cited by this paper
• Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind

  2000influential reference
• Fracture risk is increased in Crohn's disease, but not in ulcerative colitis

  2000cited by this paper
• Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study.

  1999cited by this paper
• Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

  1999cited by this paper
• Bone mineral density in steroid-dependent asthma assessed by peripheral quantitative computed tomography.

  1999cited by this paper
• Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  1999cited by this paper
• Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group.

  1999cited by this paper
• Effects of glucocorticoids on bone mineral density in rheumatoid arthritis patients

  1999cited by this paper
• A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update

  1998cited by this paper
• Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

  1998cited by this paper
• Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids

  1998cited by this paper
• Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease.

  1998cited by this paper
• Updated Data on Proximal Femur Bone Mineral Levels of US Adults

  1998cited by this paper
• The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.

  1998cited by this paper
• Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids.

  1998cited by this paper
• Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intermittent Intravenous Pamidronate: A Randomized Trial

  1997cited by this paper
• Risk factors for hip fracture in men. Hip Fracture Study Group.

  1997cited by this paper
• Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids.

  1997cited by this paper
• Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica.

  1997cited by this paper
• Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy.

  1997cited by this paper
• Risk Factors for Hip Fracture in Men

  1997cited by this paper
• Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements.

  1997cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• 96153999 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

  1996cited by this paper
• Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

  1996cited by this paper
• Trabecular and cortical bone loss in systemic lupus erythematosus.

  1996cited by this paper
• A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica

  1996cited by this paper
• Fracture after cardiac transplantation: a prospective longitudinal study.

  1996cited by this paper
• Altered trabecular architecture induced by Corticosteroids: A Bone Histomorphometric Study

  1996cited by this paper
• Bone mineral density and hormonal status in men with systemic lupus erythematosus

  1996cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines.

  1996cited by this paper
• Inhaled and oral corticosteroids: their effects on bone mineral density in older adults.

  1995cited by this paper
• Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

  1995cited by this paper
• Rheumatoid arthritis, corticosteroid therapy and hip fracture.

  1995cited by this paper
• Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis

  1995cited by this paper
• The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women.

  1995cited by this paper
• Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids.

  1995cited by this paper
• Loss of bone mineral density in premenopausal women with systemic lupus erythematosus.

  1995cited by this paper
• Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis.

  1995cited by this paper
• Rheumatoid arthritis and bone mineral density in elderly women

  1995cited by this paper
• Sex hormone status and bone mineral density in men with rheumatoid arthritis.

  1995cited by this paper
• Mechanisms of rapid bone loss following cardiac transplantation

  1994cited by this paper
• Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

  1994cited by this paper
• The evaluation of osteoporosis : dual energy x-ray absorptiometry in clinical practice

  1994cited by this paper
• Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study.

  1994cited by this paper
• Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls.

  1994cited by this paper
• Bone mineral density in patients with temporal arteritis and polymyalgia rheumatica.

  1993cited by this paper
• The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women.

  1993cited by this paper
• Loss of trabecular bone mineral density in systemic lupus erythematosus.

  1993cited by this paper
• Osteoporosis after cardiac transplantation.

  1993cited by this paper
• Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids.

  1993cited by this paper
• Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

  1993cited by this paper
• Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis

  1993influential reference
• Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone.

  1993cited by this paper
• [Changes in bone mass in hepatic cirrhosis, chronic obstructive pulmonary disease, insulin-dependent diabetes, and primary hyperparathyroidism].

  1993cited by this paper
• Normal bone mineral density following cure of Cushing's syndrome

  1992cited by this paper
• Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients

  1992cited by this paper
• Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.

  1992cited by this paper
• Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids.

  1992cited by this paper
• Lateral spine densitometry is a more sensitive indicator of glucocorticoid‐induced bone loss

  1992cited by this paper
• Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

  1992cited by this paper
• Risk of osteoporosis in men with chronic bronchitis

  1992cited by this paper
• Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.

  1992cited by this paper
• Glucocorticoid-induced osteoporosis: a cross-sectional study.

  1991cited by this paper
• Differential effects of aging and disease on trabecular and compact bone density of the radius.

  1991cited by this paper
• Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis.

  1991cited by this paper
• Predictors of fractures in early rheumatoid arthritis.

  1991cited by this paper
• Rapid loss of vertebral mineral density after renal transplantation.

  1991cited by this paper

• The role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus

  2026cites this paper
• Patient experiences of PMR: a qualitative narrative literature review

  2026cites this paper
• Differential predictive value of FRAX Hip and major osteoporotic fracture probabilities for denosumab response.

  2026cites this paper
• Modulation of inflammatory pathways by omega-3 fatty acids in knee joint health for the management of post-traumatic osteoarthritis: a review.

  2026cites this paper
• Stability-Driven Osteoporosis Screening: Multi-View Consensus Feature Selection with External Validation and Sensitivity Analysis

  2026cites this paper
• Opportunistic osteoporosis screening on FDG PET/CT scans in breast carcinoma: a comparison with DXA

  2026cites this paper
• Glucocorticoids on bone remodeling in systemic lupus erythematosus mice

  2025cites this paper
• The local inactivation of glucocorticoid as regulator for the development of glucocorticoid-induced osteoporosis

  2025cites this paper
• Metabolic musculoskeletal disorders in patients with inflammatory bowel disease

  2025cites this paper
• Basigin links altered skeletal stem cell lineage dynamics with glucocorticoid-induced bone loss and impaired angiogenesis

  2025cites this paper
• Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes

  2025cites this paper
• Hybrid Machine Learning Models and FRAX Tool for Comprehensive Osteoporosis and Fragility Fracture Risk Prediction

  2025influential citation
• Evaluation of clinical risk factors for osteoporotic fractures using the FRAX calculator among women in Armenia aged 40 and older

  2025cites this paper
• Consensus evidence-based clinical practice guide for the diagnosis and management of osteoporosis in childhood and adolescence

  2025cites this paper
• A Two-Sample Mendelian Randomization Study of Ulcerative Colitis and Osteoporosis

  2025cites this paper
• Fracture Risk Assessment in the 2023 Osteoporosis Canada Guideline

  2025cites this paper
• Impact of alcohol consumption and muscle mass on bone mineral density in metabolic dysfunction and alcohol-associated liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD).

  2025cites this paper
• Risk of Vertebral Fractures in ESKD Patients with Vasculitis

  2025cites this paper
• Special considerations of hyponatremia in the elderly patient.

  2025cites this paper
• Ovalbumin-induced asthma leads to bone loss with Piezo channel suppression in mice

  2025cites this paper
• From bench to bedside, boswellic acids in anti-inflammatory therapy — mechanistic insights, bioavailability challenges, and optimization approaches

  2025cites this paper
• Osteoporosis in Severe Asthmatic Patients: Data from the Severe Asthma Network in Italy (SANI) Registry

  2025cites this paper
• Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review

  2025cites this paper
• Diffuse Osteosclerosis in a Young Cat Presenting With Chronic Nasal Congestion: A Case Report

  2025cites this paper
• Appropriate use and complications of corticosteroids in inflammatory bowel disease: A comprehensive review.

  2025cites this paper
• A novel cohort to assess longitudinal glucocorticoid toxicity in individuals with rheumatic diseases: objectives, design, and initial baseline characteristics of the LONG-TOX cohort.

  2025cites this paper
• Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis

  2025cites this paper
• Analysis of Glucocorticoids as Potential Adulterants in Cosmetic Products: A Dual Approach for Qualitative and Quantitative Evaluation Based on ELISA and HPLC-MS Methods

  2025cites this paper
• Bone-related outcomes in patients with bullous pemphigoid: a population-based study

  2025cites this paper
• Bone Effects of Anti-Cancer Treatments in 2024

  2025cites this paper
• Effective Treatment with an Interleukin-5 Inhibitor for Recurrent Life-threatening Coronary Spastic Angina with Hypereosinophilia: A Case Report.

  2025cites this paper
• The 2024 UK clinical guideline for the prevention and treatment of osteoporosis

  2025influential citation
• Osteoporosis and fracture risk: a practical guide for neurologists

  2025cites this paper
• Exploring the Interaction Between Sjögren’s Syndrome and Osteoporosis: Pathophysiological Mechanisms and Management Strategies

  2025cites this paper
• Malnutrition and Spinal Sagittal Malalignment Are Risk Factors for Incidence of New Vertebral Fractures in Patients with Osteoporosis

  2025cites this paper
• Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study

  2025cites this paper
• Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases

  2025influential citation
• Hyponatraemia in ageing

  2025cites this paper
• Screening for Osteoporosis in Inflammatory Bowel Disease Patients at a Tertiary IBD Clinic

  2025cites this paper
• TIGAR promotes osteogenic differentiation and ameliorates glucocorticoid-induced osteoporosis via autophagy-Nrf2-ROS axis

  2025cites this paper
• The assessment and management of bone health in pediatric-onset rheumatological diseases from early age to adulthood: A critical overview.

  2025cites this paper
• Assessment of Glucocorticoid-Induced Osteoporosis Treatment by Prevailing Guidelines in a Tertiary Care Hospital

  2025cites this paper
• Immunosuppressive Therapy Following Renal Transplant

  2025cites this paper
• Oral Corticosteroids for Skin Disease in the Older Population: Minimizing Potential Adverse Effects

  2024cites this paper
• An Overlooked Medication-Induced Celiac Flare Complicating Treatment of Osteoporosis

  2024cites this paper
• Ostéoporose cortisonique

  2024cites this paper
• Trabecular Bone Score Improves Fracture Risk Discrimination in Postmenopausal Rheumatoid Arthritis Patients Receiving Glucocorticoids

  2024cites this paper
• Targeting interleukin-6 pathways in giant cell arteritis management: A narrative review of evidence.

  2024cites this paper
• Osteoporosis inducida por glucocorticoides

  2024cites this paper
• Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy.

  2024cites this paper
• Biological Heterogeneity in Susceptibility to Glucocorticoid-Induced Bone Loss: Short- and Long-Term Hip BMD Trajectories

  2024cites this paper
• Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison’s disease

  2024cites this paper
• Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan

  2024cites this paper
• Evaluation of bone health problems among a group of children with rheumatological diseases

  2024cites this paper
• What can we learn about bone density in COPD patients from a chest CT? A systematic review

  2024cites this paper
• Association between trabecular bone score, 10-year probability risk for fracture, and vertebral fractures in rheumatoid arthritis

  2024cites this paper
• Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)

  2024cites this paper
• Ukrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

  2024cites this paper
• Can a 6-Month Exercise Training Program Improve Musculoskeletal Health in Individuals with Systemic Lupus Erythematosus post Glucocorticoid Pulsetherapy? Protocol for a Randomized Controlled Trial

  2024cites this paper
• Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease

  2024cites this paper
• Teriparatide in postmenopausal osteoporosis: uncovering novel insights into efficacy and safety compared to other treatments – a systematic review and meta-analysis

  2024cites this paper
• Loss of BACH1 improves osteogenic differentiation in glucocorticoid-induced hBMSCs through restoring autophagy

  2024cites this paper
• 274th ENMC international workshop: Recommendations for optimizing bone strength in neuromuscular disorders. Hoofddorp, The Netherlands, 19-21 January 2024.

  2024cites this paper
• Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology.

  2024cites this paper
• Effects of Denosumab and Bisphosphonates on Glucocorticoid-induced Osteoporosis in Patients with Neuroimmunological Disorders

  2024cites this paper
• Neuroprotective macromolecular methylprednisolone prodrug nanomedicine prevents glucocorticoid-induced muscle atrophy and osteoporosis in a rat model of spinal cord injury.

  2024cites this paper
• Responsible Use of Oral Corticosteroids in People with Comorbid Diabetes: An Expert Consensus.

  2024cites this paper
• Remitting seronegative symmetrical synovitis with pitting edema syndrome: case report of an atypical presentation of a rare syndrome and literature review

  2024cites this paper
• Use of corticosteroids in non-infectious uveitis – expert consensus in Taiwan

  2024cites this paper
• The association between myasthenia gravis and risk of fracture: a systematic review and meta-analysis

  2024cites this paper
• Association between daily consumption of spicy food and bone mineral density in middle-aged and older adults: a cross-sectional study.

  2024cites this paper
• The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34)

  2024cites this paper
• Current Challenges and Future Directions in the Assessment of Glucocorticoid Status

  2024cites this paper
• Ten tips on how to assess bone health in patients with chronic kidney disease

  2024cites this paper
• Practical evaluation of risk factors in patients with osteoporosis-induced thoracic and lumbar vertebral compression fractures requiring surgery

  2024cites this paper
• Low-dose glucocorticoid increase the risk of fracture in postmenopausal women with low bone mass: a retrospective cohort study

  2024cites this paper
• The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity

  2024cites this paper
• Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: A cross-sectional study at a health examination center.

  2024cites this paper
• Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users

  2024cites this paper
• Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials.

  2024cites this paper
• Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)

  2024cites this paper
• Do patients with nephrotic syndrome have an increased risk of osteoporosis? A nationwide population-based retrospective cohort study in Taiwan

  2024cites this paper
• Trattamento dell’osteoporosi da glucocorticoidi

  2024cites this paper
• Bone Density and Trabecular Bone Score Decline Rapidly in the First Year After Bone Marrow Transplantation with a Marked Increase in 10-Year Fracture Risk

  2024cites this paper
• Bone loss over time and risk of osteoporosis in advanced pancreatic cancer.

  2024cites this paper
• A comprehensive review on glucocorticoids induced osteoporosis: A medication caused disease.

  2024cites this paper
• Terapia corticosteroidea nella pratica reumatologica

  2024cites this paper
• Glucocorticoid-induced osteoporosis—from molecular mechanism to clinical practice

  2024cites this paper
• Influence of budesonide and fluticasone propionate in the anti-osteoporotic potential in human bone marrow-derived mesenchymal stem cells via stimulation of osteogenic differentiation

  2024cites this paper
• circNDUFA13 stimulates adipogenesis of bone marrow-derived mesenchymal stem cells via interaction with STAT3

  2024cites this paper
• Corticothérapie en pratique rhumatologique

  2023cites this paper
• Evaluation of Bone Mineral Density in Lung Transplant Recipients by Chest Computed Tomography

  2023cites this paper
• Exploitation of steroids in coronavirus disease 2019: An overview

  2023cites this paper
• Limited beneficial effects of systemic steroids when added to standard of care treatment of seasonal allergic rhinitis

  2023cites this paper
• An Update on Drug–Nutrient Interactions and Dental Decay in Older Adults

  2023cites this paper
• Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

  2023cites this paper
• Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves’ orbitopathy

  2023cites this paper
• Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency

  2023cites this paper
• Chronic Steroid Use, Complications, and Readmission Following Open Reduction Internal Fixation of Distal Radius Fracture

  2023cites this paper
• Bone health in inflammatory bowel disease

  2023cites this paper